Be the first person to write a business review for Henderson Morley plc

Heska Corporation develops, manufactures, markets, sells, and supports veterinary products for the canine and feline companion animal health markets. It operates in two segments, Core Companion Animal Health; and Other Vaccines, Pharmaceuticals, and Products. The Core Companion Animal Health segment offers veterinary diagnostic and other instruments, including handheld blood analyzers, veterinary chemistry analyzers, veterinary hematology analyzers, IV pumps, and consumable supplies; point-of-care diagnostic and other tests, such as heartworm diagnostic tests for dogs and cats, and early renal damage detection products; and veterinary diagnostic laboratory products and services, which comprise allergy diagnostic products and services, as well as ERD Reagent Packs used to detect microalbuminuria. It provides pharmaceuticals and supplements, such as heartworm prevention products, nutritional supplements, and hypothyroid treatment products; and vaccines and other biologicals for the treatment of allergies and feline respiratory diseases.This segment sells its products to veterinarians directly, as well as through telephone sales force, independent third party distributors, and other distribution relationships. The Other Vaccines, Pharmaceuticals, and Products segment provides private label vaccines and pharmaceuticals primarily for cattle, as well as for other animals, including small mammals and fish. It offers bovine vaccines, and biological and pharmaceutical products for other animal health companies, as well as provides turnkey services, which consist of research, licensing, production, labeling, and packaging of products, as well as validation support and distribution services. This segment sells its products through third parties under third party labels. The company was formerly known as Paravax, Inc. and changed its name to Heska Corporation in 1995. Heska Corporation was founded in 1988 and is headquartered in Loveland, Colorado.

Hollis-Eden Pharmaceuticals, Inc. company was founded in 1992 and is headquartered in San Diego, California. Hollis-Eden Pharmaceuticals Inc., a development stage pharmaceutical company, engages in the discovery and development of products for the treatment of diseases and disorders, in which the body is unable to mount immune or metabolic response due to disease or the process of aging. The company focuses on developing a series of adrenal steroid hormones and hormone analogs that are derived from its Hormonal Signaling Technology Platform. It develops two clinical drug development candidates, TRIOLEX (HE3286), which is in initial clinical trials for the treatment of type 2 diabetes, ulcerative colitis, and rheumatoid arthritis; and APOPTONE (HE3235) that is in a clinical trial for late-stage prostate cancer. The company is also exploring APOPTONE for other cancers, such as breast cancer. In addition, Hollis-Eden Pharmaceuticals has a research program that is generating clinical leads for evaluation in preclinical models of various diseases, including metabolic and autoimmune conditions, as well as inflammatory diseases of the lung, bone metabolism, and regenerative medicine.

Human Genome Sciences, Inc. was founded in 1992 and is headquartered in Rockville, Maryland. Human Genome Sciences, Inc. operates as a biopharmaceutical company in the United States. The company's clinical development pipeline includes novel drugs to treat hepatitis C, lupus, inhalation anthrax, and cancer. It focuses on the commercialization of Albuferon (albinterferon alfa-2b) for hepatitis C and LymphoStat-B (belimumab) for lupus. The company has completed Phase III development trials for Albuferon and is conducting two Phase III clinical trials of LymphoStat-B. It also delivers doses of ABthrax (raxibacumab) to the U.S. Strategic National Stockpile for use in the event of an emergency for the treatment of inhalation anthrax. In addition, the company has various drugs in the earlier stages of clinical development for the treatment of cancer, led by the TRAIL receptor antibody HGS-ETR1 and a small-molecule antagonist of IAP (inhibitor of apoptosis) proteins. Further, Human Genome Sciences, Inc., through a strategic collaboration agreement with GlaxoSmithKline, has substantial financial rights to certain products in the GlaxoSmithKline clinical pipeline, including darapladib that is in Phase III development as a treatment for coronary heart disease; and Syncria (albiglutide), which is in Phase III development as a treatment for type 2 diabetes. Additionally, it has a strategic commercial collaboration agreement with Novartis International Pharmaceutical, Ltd. for the co-development and commercialization of Albuferon; and a strategic licensing and collaboration agreement with Aegera Therapeutics, Inc. to develop and commercialize HGS1029 and other small-molecule inhibitors of IAP (inhibitor of apoptosis) proteins in oncology.

Huntingdon Life Sciences Limited, a subsidiary of Life Sciences Research, is a leading contract research organization (CRO) that tests the safety of agrochemicals, foods, flavorings, industrial chemicals, pharmaceuticals and veterinary products. Huntingdon Life Sciences also provides drug development services for biotechnology and pharmaceutical companies, including Phase I-III testing, genetic toxicology assays, and microbiological activities.

Hybrigenics wants to open a new pathway towards the fight against cancer. Established in 1997, the drug discovery company zeroes in on new drug targets and therapeutic biological components with the help of its computer programs involving protein sequencing and other high tech chemical screening techniques. What separates it from other drug researching companies is its Laboratory Information Management System (LIMS), a product that commercializes its library screening and navigating capabilities regarding DNA and other related biological sequencing. With its headquarters in Paris, Hybrigenics also owns Semaia BV, a subsidiary located in the Netherlands, and an additional office in the US.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.